BEACON Trial Investigation Results - Internal investigation indicates anomalous efficacy results in the BEACON trial are likely due to patient-specific factors rather than issues with the drug product or study conduct[23] - A KOL panel review suggested that 9 out of 10 patients who did not respond in the US may not have had CSU, highlighting potential misdiagnosis issues common in CSU studies where 25%-30% of patients are incorrectly diagnosed[40] - Redosing Cohort 8 & 9 patients with a different drug product lot did not significantly change efficacy outcomes, with no incremental efficacy observed in 8 of 9 patients redosed[27, 31] - In the BEACON trial, 7 of 10 US patients in Cohorts 8 & 9 were switched to a different drug product lot by week 16[27, 31] ETESIAN Trial Interim Results - A single 180mg dose of Briquilimab in the ETESIAN study demonstrated a reduction in serum tryptase levels at 6 weeks, consistent with previous observations[45] - Briquilimab mitigated the effects of allergen challenge on FEV1 response, showing a sustained impact on asthmatic response at 6 and 12 weeks[47] - Briquilimab dramatically reduced airway hyper-responsiveness, increasing the concentration of methacholine needed to drive a 20% drop in FEV1 (PD20)[51] - Sputum eosinophil response was suppressed by Briquilimab at both 6-week and 12-week allergen challenge timepoints[53] Program Status and Next Steps - In CSU, single doses of 240mg and 360mg of Briquilimab led to more than a 24-point drop in UAS7, with 82% CR and 91% WC disease by week 4 (n=11)[60] - In an OLE study for CSU, 180mg Q8W of Briquilimab resulted in 73% CR and 82% WC disease at 12 weeks (n=11)[60]

Core Viewpoint - A class action lawsuit has been filed against Jasper Therapeutics, Inc. for allegedly misleading investors regarding the commercial prospects of its lead product candidate, Briquilimab, during the period from November 30, 2023, to July 3, 2025 [1][2]. Allegations - The lawsuit claims that Jasper Therapeutics failed to disclose critical information, including: - Lack of necessary controls and procedures to ensure third-party manufacturers complied with cGMP regulations [2]. - Increased risk of confounding results in ongoing studies, negatively impacting regulatory and commercial prospects [2]. - Heightened likelihood of disruptive cost-reduction measures [2]. - Overstated business and financial prospects, as well as the clinical and commercial prospects of Briquilimab [2]. Stock Price Impact - Following the revelation of these issues on July 7, 2025, Jasper's stock price plummeted by $3.73 per share, representing a 55.1% decline, closing at $3.04 per share [3]. Class Action Participation - Shareholders may be eligible to participate in the class action and can contact Robbins LLP if they wish to serve as lead plaintiffs [4]. - Participation in the case is not required to be eligible for recovery, and shareholders can remain absent class members if they choose [4]. Firm Background - Robbins LLP is noted for its focus on shareholder rights litigation, helping shareholders recover losses and improve corporate governance since 2002 [5].

Core Viewpoint - A class action lawsuit has been filed against Jasper Therapeutics, Inc. for allegedly misleading investors regarding the commercial prospects of its lead product candidate, briquilimab [1][2]. Allegations - The lawsuit claims that Jasper Therapeutics failed to disclose critical information about its manufacturing controls and procedures, which could affect the clinical trial results and the commercial viability of its products [2]. - Specific allegations include the lack of necessary controls for third-party manufacturers, increasing the risk of confounded study results, and overstating the company's financial and clinical prospects [2]. Stock Price Impact - Following the revelation of these issues on July 7, 2025, Jasper's stock price plummeted by $3.73 per share, representing a 55.1% decline, closing at $3.04 per share [3]. Class Action Participation - Shareholders interested in participating as lead plaintiffs must file their papers by November 18, 2025, although participation is not required to be eligible for recovery [4]. Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless the case is won [5].

Core Viewpoint - A class action lawsuit has been filed against Jasper Therapeutics, Inc. for allegedly misleading investors regarding the commercial prospects of its lead product candidate, Briquilimab, which has resulted in significant stock price decline [1][2][3]. Group 1: Allegations and Issues - The lawsuit claims that Jasper Therapeutics failed to disclose critical information about its manufacturing controls and procedures, which were necessary to ensure compliance with cGMP regulations [2]. - This lack of disclosure allegedly increased the risk of confounding results in ongoing studies, negatively impacting the regulatory and commercial prospects of the company's products, including Briquilimab [2]. - The failure to maintain proper controls also raised the likelihood of disruptive cost-reduction measures, leading to overstated business and financial prospects for the company [2]. Group 2: Stock Price Impact - Following the revelation of these issues on July 7, 2025, Jasper's stock price plummeted by $3.73 per share, representing a 55.1% decrease, closing at $3.04 per share [3]. Group 3: Class Action Participation - Shareholders of Jasper Therapeutics may be eligible to participate in the class action and can contact Robbins LLP if they wish to serve as lead plaintiffs [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4].

Core Viewpoint - A class action lawsuit has been filed against Jasper Therapeutics, Inc. for allegedly misleading investors regarding the commercial prospects of its lead product candidate, briquilimab [1][2]. Group 1: Allegations - The lawsuit claims that Jasper Therapeutics failed to disclose critical information about its manufacturing controls and procedures, which were necessary to ensure compliance with cGMP regulations [2]. - The lack of proper controls increased the risk of confounding results in ongoing studies, negatively impacting the regulatory and commercial prospects of the company's products, including briquilimab [2]. - This situation heightened the likelihood of disruptive cost-reduction measures, leading to an overstatement of the company's business and financial prospects [2]. Group 2: Stock Price Impact - Following the revelation of these issues on July 7, 2025, Jasper's stock price plummeted by $3.73 per share, representing a 55.1% decline, closing at $3.04 per share [3]. Group 3: Class Action Participation - Shareholders who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be eligible to participate in the class action [1][4]. - Interested shareholders can contact Robbins LLP to serve as lead plaintiff or remain as absent class members without participating in the case [4].